Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Chee Hae | - |
dc.contributor.author | Han, Kyung Ah | - |
dc.contributor.author | Yu, Jaemyung | - |
dc.contributor.author | Lee, Sang Hak | - |
dc.contributor.author | Jeon, Hui Kyung | - |
dc.contributor.author | Kim, Sang Hyun | - |
dc.contributor.author | Kim, Seok Yeon | - |
dc.contributor.author | Han, Ki Hoon | - |
dc.contributor.author | Won, Kyungheon | - |
dc.contributor.author | Kim, Dong-Bin | - |
dc.contributor.author | Lee, Kwang-Jae | - |
dc.contributor.author | Min, Kyungwan | - |
dc.contributor.author | Byun, Dong Won | - |
dc.contributor.author | Lim, Sang-Wook | - |
dc.contributor.author | Ahn, Chul Woo | - |
dc.contributor.author | Kim, SeongHwan | - |
dc.contributor.author | Hong, Young Joon | - |
dc.contributor.author | Sung, Jidong | - |
dc.contributor.author | Hur, Seung-Ho | - |
dc.contributor.author | Hong, Soon Jun | - |
dc.contributor.author | Lim, Hong-Seok | - |
dc.contributor.author | Park, Le Byung | - |
dc.contributor.author | Kim, In Joo | - |
dc.contributor.author | Lee, Hyoungwoo | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2021-09-02T17:03:38Z | - |
dc.date.available | 2021-09-02T17:03:38Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-01 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/78455 | - |
dc.description.abstract | Purpose: The purpose of this study was to examine the efficacy and safety of adding omega-3 fatty acids to rosuvastatin in patients with residual hypertriglyceridemia despite statin treatment. Methods: This study was a multicenter, randomized, double-blind, placebo-controlled study. After a 4-week run-in period of rosuvastatin treatment, the patients who had residual hypertriglyceridemia were randomized to receive rosuvastatin 20 mg/d plus omega-3 fatty acids 4 g/d (ROSUMEGA group) or rosuvastatin 20 mg/d (rosuvastatin group) with a 1:1 ratio and were prescribed each medication for 8 weeks. Findings: A total of 201 patients were analyzed (mean [SD] age, 58.1 [10.7] years; 62.7% male). After 8 weeks of treatment, the percentage change from baseline in triglycerides (TGs) and non-HDL-C was significantly greater in the ROSUMEGA group than in the rosuvastatin group (TGs: -26.3% vs -11.4%, P < 0.001; non-HDL-C: -10.7% vs -2.2%, P = 0.001). In the linear regression analysis, the lipid-lowering effect of omega-3 fatty acids was greater when baseline TG or non-HDL-C levels were high and body mass index was low. The incidence of adverse events was not significantly different between the 2 groups. (C) 2018 The Authors. Published by Elsevier HS Journals, Inc. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.subject | CORONARY-HEART-DISEASE | - |
dc.subject | ESTER AMR101 THERAPY | - |
dc.subject | NON-HDL CHOLESTEROL | - |
dc.subject | CARDIOVASCULAR-DISEASE | - |
dc.subject | EICOSAPENTAENOIC ACID | - |
dc.subject | HIGH-RISK | - |
dc.subject | TRIGLYCERIDE LEVELS | - |
dc.subject | METABOLIC SYNDROME | - |
dc.subject | FATTY-ACIDS | - |
dc.title | Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, SeongHwan | - |
dc.contributor.affiliatedAuthor | Hong, Soon Jun | - |
dc.identifier.doi | 10.1016/j.clinthera.2017.11.007 | - |
dc.identifier.scopusid | 2-s2.0-85039991220 | - |
dc.identifier.wosid | 000423137800010 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.40, no.1, pp.83 - 94 | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 40 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 83 | - |
dc.citation.endPage | 94 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.subject.keywordPlus | CORONARY-HEART-DISEASE | - |
dc.subject.keywordPlus | ESTER AMR101 THERAPY | - |
dc.subject.keywordPlus | NON-HDL CHOLESTEROL | - |
dc.subject.keywordPlus | CARDIOVASCULAR-DISEASE | - |
dc.subject.keywordPlus | EICOSAPENTAENOIC ACID | - |
dc.subject.keywordPlus | HIGH-RISK | - |
dc.subject.keywordPlus | TRIGLYCERIDE LEVELS | - |
dc.subject.keywordPlus | METABOLIC SYNDROME | - |
dc.subject.keywordPlus | FATTY-ACIDS | - |
dc.subject.keywordAuthor | combination | - |
dc.subject.keywordAuthor | hypertriglyceridemia | - |
dc.subject.keywordAuthor | non-HDL-C | - |
dc.subject.keywordAuthor | omega-3 fatty acids | - |
dc.subject.keywordAuthor | rosuvastatin | - |
dc.subject.keywordAuthor | triglycerides | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.